Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | NHERF1 | O14745 | 2/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.39 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.39 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6713155 | 0.91 | SERPINE1 (0.48) | NHERF1GRIK1PLCG2SERPINE1STK33 | |
| SCHEMBL6711794 | 0.90 | ALDH1A1 (0.46) | CHRNB2CHRNB4CHRNA3CHRNA4GRIK1 | |
| SCHEMBL6712036 | 0.90 | KCNMA1 (0.45) | NHERF1GRIK1PLCG2STK33KDM4E | |
| SCHEMBL6710141 | 0.90 | GRIK1 (0.44) | NHERF1GRIK1PLCG2SERPINE1STK33 | |
| SCHEMBL6707858 | 0.89 | MEN1 (0.47) | GRIK1PLCG2MAPTTDP1 | |
| SCHEMBL6709960 | 0.88 | CHRNB2 (0.41) | CHRNB2CHRNB4CHRNA3CHRNA4MAPT | |
| SCHEMBL6708655 | 0.87 | NHERF1 (0.46) | NHERF1GRIK1PLCG2STK33 | |
| SCHEMBL6713646 | 0.87 | NHERF1 (0.40) | NHERF1GRIK1PLCG2KDM4E | |
| SCHEMBL6708859 | 0.86 | PLA2G7 (0.41) | NHERF1GRIK1PLCG2 | |
| SCHEMBL6709173 | 0.86 | GRIK1 (0.44) | NHERF1GRIK1PLCG2STK33KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | CHRNB2 4882/4885CHRNB4 4880/4885CHRNA3 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.